SLC5A2 and hydrops fetalis: However, the main limitation of current AI-ECG trials is the use of data which predates the introduction of novel HF medications such as ARNIs and SGLT2 inhibitors, both of which have independently improved long-term outcomes for modern-day HF patients [124,160,161].